SEH1 like nucleoporinGenealiases: SEC13L · SEH1A · SEH1B · Seh1
Q-omics provides the consensus-scored SEH1L profile across patient tissues and cancer cell-line models. SEH1L expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, SEH1L is differentially expressed in 16, with the highest sampling consensus in STAD. Additionally, SEH1L protein abundance shows 24,898 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight LIHC, STAD, and GBM as cancer lineages where SEH1L shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEH1L — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEH1L survival associations across molecular data types. SEH1L RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEH1L RNA expression–survival associations across cancer types. High SEH1L expression shows unfavorable associations in LIHC, ACC, HNSC, UVM and KICH, but favorable associations in KIRC. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for SEH1L RNA expression.
This table summarizes SEH1L tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 5. The strongest signals are observed in STAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for SEH1L. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEH1L shows higher tumor expression in STAD, LIHC, HNSC, LUSC, COAD and KIRC. The STAD box plot shows higher SEH1L RNA expression in tumor versus normal tissue (log2 FC = +1.152, t-test p < 0.001).
This table shows molecular features associated with SEH1L in patient tissues and cancer cell lines. In patient samples, SEH1L shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, SEH1L RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and BLOOD_Lymphoma.
